An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)
Public ClinicalTrials.gov record NCT05757570. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.
Study identification
- NCT ID
- NCT05757570
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 3, 2023 (Actual)
- Primary completion
- Aug 12, 2026 (Actual)
- Completion
- Aug 12, 2026 (Actual)
- Last update posted
- Sep 14, 2026
2023 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site (230) | Los Angeles | California | 90033 | — |
| Investigational Site (401) | Washington D.C. | District of Columbia | 20007 | — |
| Investigational Site (419) | Cooper City | Florida | 33024 | — |
| Investigational Site (425) | Miami | Florida | 33143 | — |
| Investigational Site (219) | Iowa City | Iowa | 52242 | — |
| Investigational Site (435) | Columbia | Maryland | 21044 | — |
| Investigational site (405) | Lake Success | New York | 11042 | — |
| Investigational Site (423) | New Hyde Park | New York | 11040 | — |
| Investigational Site (421) | New York | New York | 10028 | — |
| Investigational Site (404) | New York | New York | 10065 | — |
| Investigational Site (420) | Shirley | New York | 11967 | — |
| Investigational Site (422) | The Bronx | New York | 10469 | — |
| Investigational Site (414) | Charlotte | North Carolina | 28204 | — |
| Investigational Site (402) | Greenville | North Carolina | 27834 | — |
| Investigational Site (411) | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05757570, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05757570 live on ClinicalTrials.gov.